Inactivated Avian Infectious Bronchitis Virus Strains M41 and 4-91 Provide Broad Protection Against Multiple Avian...

Area of Science:

• Veterinary Virology
• Poultry Health Management
• Vaccine Development

Background:

• Infectious Bronchitis Virus (IBV) causes significant economic losses in the poultry industry.
• Current IBV vaccination strategies face challenges due to emerging IBV variants.
• A novel nine-valent inactivated vaccine (Nobilis Multriva) was developed, including two IBV strains (M41 and 4-91).

Purpose of the Study:

• To investigate the efficacy of the Nobilis Multriva inactivated vaccine against homologous and heterologous IBV strains.
• To evaluate the vaccine's protective capabilities in both Specific Pathogen Free (SPF) and commercial chickens.

Main Methods:

• Administration of the inactivated IBV vaccine (Nobilis Multriva) intramuscularly, with or without prior priming.
• Challenge of vaccinated birds with homologous and heterologous IBV strains at different production stages.
• Evaluation of vaccine efficacy through serological assays, clinical observations, and egg production monitoring.

Main Results:

• The vaccine demonstrated broad protection against diverse IBV strains (M41, 4-91, QX, Q1, Var2).
• Sustained serological response against IBV M41 and 4-91 was observed up to 96 weeks of age.
• The vaccine simplifies vaccination protocols, reducing bird stress, labor, and costs.

Conclusions:

• The nine-valent inactivated vaccine (Nobilis Multriva) provides broad cross-protection against multiple IBV strains.
• The vaccine ensures long-lasting immune responses, crucial for layers and breeder birds.
• Nobilis Multriva is a valuable tool for effective IBV control in the poultry sector.